Randomized Crossover Study of the Efficacy and Safety of Sevelamer Hydrochloride and Lanthanum Carbonate in Japanese Patients Undergoing Hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 4, 2012, Pages 341-349

  Kasai, Satoshi ^a   Sato, Kazuto ^a   Murata, Yaeko ^b   Kinoshita, Yasumichi ^a  

^a JAPANESE RED CROSS SOCIETY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Crossover study; Hemodialysis; Hyperphosphatemia; Lanthanum carbonate; Sevelamer hydrochloride

Indexed keywords

CALCIUM; FORENOL; LANTHANUM CARBONATE; PHOSPHATE; SEVELAMER; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE HEART INFARCTION; ADULT; ADVERSE DRUG REACTION; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHOLECYSTITIS; CLINICAL ARTICLE; COMMON BILE DUCT STONE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMORAL ABSCESS; HEMODIALYSIS; HEMODYNAMICS; HUMAN; INTERVERTEBRAL DISK HERNIA; JAPANESE; MALE; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHUNT MALFUNCTION; SINGLE BLIND PROCEDURE; STENOINSUFFICIENCY; VIRUS PERICARDITIS;

ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM; CHELATING AGENTS; CONSTIPATION; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; MALE; PHOSPHATES; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84864121585     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01071.x     Document Type: Article

References (26)

1. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007;146:177-83.
2. Collins AJ, Foley R, Herzog C etal. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008;51(Suppl 1):S1-320.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis patients. J Am Soc Nephrol 2004;15:2208-18.
4. Tentori F, Blayney MJ, Albert JM etal. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201.
6. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-25.
7. Goodman WG, Goldin J, Kuizon BD etal. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
8. Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991;324:527-31.
9. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1979;1:406-9.
10. Chertow GM, Burke SK, Lazarus JM etal. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
11. D'Haese PC, Spasovski GB, Sikole A etal. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-8.
12. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009;72:252-8.
13. Arenas MD, Rebollo P, Malek T etal. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol 2010;23:683-92.
14. Filiopoulos V, Koutis I, Trompouki S etal. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Ther Apher Dial 2011;15:20-7.
15. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96:2818-27.
16. Finn WF, SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65:191-202.
17. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6years of treatment. Nephron Clin Pract 2008;110:c15-23. Erratum in: Nephron Clin Pract 2008;110:c15-c23.
18. Koiwa F, Onoda N, Kato H etal. ROD 21 Clinical Research Group. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
19. Hutchison AJ, Maes B, Vanwalleghem J etal. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005;100:c8-19. Erratum in: Nephron Clin Pract 2008;110:c15-c23.
20. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 2004;90:S39-45.
21. Hirose S, Nakanishi S, Kim J, Fukagawa M. The estimation of bicarbonate concentration in hemodialysis patients from blood biochemical values. JSDT 2010;43:919-23. (In Japanese with English summary)
22. Chan WL, Rounsley K, Chapman E etal. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders. J Ren Nutr 2010;20:270-7.
23. Behets GJ, Verberckmoes SC, Oste L etal. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005;67:1830-6.
24. Spasovski GB, Sikole A, Gelev S etal. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1year of treatment with lanthanum carbonate and after 2years of follow-up. Nephrol Dial Transplant 2006;21:2217-24.
25. Bronner F, Slepchenko BM, Pennick M, Damment SJ. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47:543-52.
26. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 2011;15:176-84.